M&A / Deals Symeres and Ambagon collaborate for colorectal cancer molecules Pharmaceutical Business ReviewThe partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins.M&A / DealsOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. M&A / DealsOncologyRead full story Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026